Biodexa Pharmaceuticals plc American Depositary Shs (BDRX)
How it compares with the broader market is one of its lowest-scoring factors — business numbers score is below the middle, while price trend score is near the bottom of its range.
BDRX scores higher than 3% of the 1,101 tickers we compare it with (Health Care).
As of 10 October 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) scores 17 out of 100 on the Market Census six-factor composite, which puts it at the Low score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.02× 30-day average
- 52-week range
- 0.45 – 52.05
- Market cap
- —
- Earnings date
- —
- Volume
- 157,835
- Avg. volume (30d)
- 7,118,773
- Open
- 0.52
- Previous close
- 0.52
- Day's range (regular session)
- 0.45 – 0.52
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 1.18
- P/E (TTM)
- —
- EPS (TTM)
- -0.01
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
What the score says about BDRX right now
Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) currently scores 17/100 on the Market Census six-factor composite, at the Low score level. BDRX is -12.13% on the day and -25.76% over five sessions as of the most recent tick. Low is the lowest level. Much of BDRX's data reads poorly right now. Market Census does not tell you to short it; the level only describes the data. BDRX's strongest factor is market mood at 50/100 — a fairly good read on the overall market. The market mood is the same for every ticker at a given moment, so it says nothing about BDRX itself. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See BDRX in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent BDRX news
Latest headlines that name Biodexa Pharmaceuticals plc American Depositary Shs, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- The Longview: Fireside Chat with Biodexa CEO Stephen StampYahoo
- BDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 PatientsYahoo
- Interim results for the six months ended June 30, 2026Yahoo
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to BDRX’s 17, all within 1 point.
Sorted by closeness to BDRX’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.